LPS (ligand for toll-like receptors, TLR4/TLR2) [41,46] or lipomannan (ligand for TLR2) [47] enhances the incidence and severity of the antibody initiated disease by decreasing the threshold for arthritis induction. The gene discussed is TLR2; the disease is arthritic joint disease.